{"schema_version":"secwatch.filing_event.v1","accession":"0000875320-22-000022","form_type":"8-K","ticker":"VRTX","cik":"0000875320","company_name":"VERTEX PHARMACEUTICALS INC / MA","filed_at":"2022-07-11T23:59:59+00:00","discovered_at":"2026-05-14T18:03:58.387411+00:00","generated_at":"2026-06-24T17:54:27.694329+00:00","sec_items":["8.01","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Vertex acquires ViaCyte for $320M cash to accelerate T1D stem cell therapy VX-880","bullets":["Vertex to acquire ViaCyte for $320 million in cash; ViaCyte becomes wholly owned subsidiary.","Goal is to accelerate development of VX-880, Vertex's investigational stem cell-derived islet therapy for T1D.","ViaCyte brings complementary tools: stem cell lines, IP, GMP manufacturing, and hypoimmune assets via CRISPR collaboration.","Acquisition expected to close later this year, subject to HSR waiting period and other customary conditions."],"urls":{"canonical":"https://secwatch.observer/filing/0000875320-22-000022","json":"https://secwatch.observer/filing/0000875320-22-000022.json","markdown":"https://secwatch.observer/filing/0000875320-22-000022.md","text":"https://secwatch.observer/filing/0000875320-22-000022.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/875320/000087532022000022/0000875320-22-000022-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/875320/000087532022000022/vrtx-20220709.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-24T17:54:27.694329+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}